TABLE 4.
Sensitivity analysis results
| Analysis | High- risk patients (n) | Events with current usual care (n) | Events with combination therapy (n) | Events averted with combination therapy (n) |
|---|---|---|---|---|
| Base-case | 2,246,005 | 609,805 | 466,763 | 143,042 |
| Population prevalence | ||||
| ICES diabetes prevalence | 2,460,631 | 662,932 | 507,428 | 155,503 |
| Event risk | ||||
| UKPDS equation | 2,246,005 | 674,559 | 516,328 | 158,231 |
| 20% lower event risk | 2,246,005 | 482,467 | 369,295 | 113,172 |
| 20% higher event risk | 2,246,005 | 740,195 | 566,568 | 173,627 |
| Relative risk reduction | ||||
| Lower 95% CI | 2,246,005 | 609,805* | 514,696 | 95,109 |
| Upper 95% CI | 2,246,005 | 609,805* | 399,220 | 210,585 |
*
The number of events does not change because these were calculated from the risk factor profile using the risk equations. ICES Institute for Clinical Evaluative Sciences; UKPDS United Kingdom Prospective Diabetes Study